(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/260092 A1

(51) International Patent Classification:
C07D 401/12 (2006.01) *A61K 31/496* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/EP2021/067304

(22) International Filing Date:
24 June 2021 (24.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/044,095 25 June 2020 (25.06.2020) US
63/120,351 02 December 2020 (02.12.2020) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85 Södertälje (SE).

(72) Inventors: **PACKER, Martin, John**; AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, Cambridgeshire CB2 0AA (GB). **DEGORCE, Sebastien, Louis**; AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, Cambridgeshire CB2 0AA (GB). **JOHANNES, Jeffrey, Wallace**; AstraZeneca R&D, Boston 35 Gatehouse Drive, Waltham, MA 02451 (US). **HANDE, Sudhir, Mahadeo**; AstraZeneca R&D, Boston 35 Gatehouse Drive, Waltham, MA 02451 (US). **GHOSH, Avipsa**; AstraZeneca R&D, Boston 35 Gatehouse Drive, Waltham, MA 02451 (US). **ZHENG, Xiaolan**; AstraZeneca R&D, Boston 35 Gatehouse Drive, Waltham, MA 02451 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building Granta Park, Cambridge, Cambridgeshire CB21 6GH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

WO 2021/260092 A1

(54) Title: QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS



(I)

(57) Abstract: The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine.